Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-03-15
DOI
10.3389/fonc.2017.00026
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
- (2016) H. M. Weir et al. CANCER RESEARCH
- Evolving Role of the Estrogen Receptor as a Predictive Biomarker:ESR1Mutational Status and Endocrine Resistance in Breast Cancer
- (2016) Josh Lauring et al. JOURNAL OF CLINICAL ONCOLOGY
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
- (2016) Paul E. Goss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
- (2016) A Harrod et al. ONCOGENE
- Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital
- (2016) A. Bardia et al. ONCOLOGIST
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
- (2016) Jill M. Spoerke et al. Nature Communications
- Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
- (2016) Christopher A. Miller et al. Nature Communications
- Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
- (2016) Florian Clatot et al. Oncotarget
- Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
- (2016) Brendon Ladd et al. Oncotarget
- Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
- (2016) Sean W Fanning et al. eLife
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
- (2016) Sarat Chandarlapaty et al. JAMA Oncology
- Targeted therapies for ER+/HER2- metastatic breast cancer
- (2015) Mutsuko Yamamoto-Ibusuki et al. BMC Medicine
- Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
- (2015) Gayathri Nagaraj et al. BREAST CANCER RESEARCH AND TREATMENT
- ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
- (2015) D. Chu et al. CLINICAL CANCER RESEARCH
- Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer
- (2015) D. S. Guttery et al. CLINICAL CHEMISTRY
- Short report: MonitoringESR1mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer
- (2015) David Sefrioui et al. INTERNATIONAL JOURNAL OF CANCER
- Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights
- (2015) Charlotte K. Y. Ng et al. JNCI-Journal of the National Cancer Institute
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Estrogen receptors in breast carcinogenesis and endocrine therapy
- (2015) Bo Huang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Clinical management of breast cancer heterogeneity
- (2015) Dimitrios Zardavas et al. Nature Reviews Clinical Oncology
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
- (2015) Gaia Schiavon et al. Science Translational Medicine
- Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens
- (2015) Takashi Takeshita et al. Translational Research
- Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
- (2015) Jiaxin Niu et al. OncoTargets and Therapy
- Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights
- (2015) Charlotte K. Y. Ng et al. JNCI-Journal of the National Cancer Institute
- Optimal management of hormone receptor positive metastatic breast cancer in 2016
- (2015) Tomas Reinert et al. Therapeutic Advances in Medical Oncology
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
- (2014) F. Cardoso et al. BREAST
- Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1
- (2014) Y. Wang et al. CANCER RESEARCH
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
- (2014) M. Yu et al. SCIENCE
- Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
- (2014) D. A. Haber et al. Cancer Discovery
- D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
- (2013) K. Merenbakh-Lamin et al. CANCER RESEARCH
- Use of SERMs for treatment in postmenopausal women
- (2013) JoAnn V. Pinkerton et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- (2013) Shunqiang Li et al. Cell Reports
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
- (2010) Y H Chia et al. BRITISH JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started